103 related articles for article (PubMed ID: 3783202)
1. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy.
Rouëssé J; Friedman S; Sarrazin D; Mouriesse H; Le Chevalier T; Arriagada R; Spielmann M; Papacharalambous A; May-Levin F
J Clin Oncol; 1986 Dec; 4(12):1765-71. PubMed ID: 3783202
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors.
Rouëssé J; Friedman S; Mouriesse H; Sarrazin D; Spielmann M
Breast Cancer Res Treat; 1990 Jul; 16(1):15-22. PubMed ID: 2207344
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of inflammatory cancer of the breast. Combined chemotherapy and radiotherapy. Apropos of 270 women treated at the Institut Gustave-Roussy].
Rouëssé J; Sarrazin D; Spielmann M; Le Chevalier T; Oudinot P; Guasch Jordan I; Mouriesse H; Levin FM
Bull Cancer; 1989; 76(1):87-92. PubMed ID: 2713518
[TBL] [Abstract][Full Text] [Related]
4. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Bourgier C; Pessoa EL; Dunant A; Heymann S; Spielmann M; Uzan C; Mathieu MC; Arriagada R; Marsiglia H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):690-5. PubMed ID: 21277101
[TBL] [Abstract][Full Text] [Related]
5. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
7. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
9. [Alternating chemotherapy and hyperfractionated accelerated radiotherapy in non-metastatic inflammatory breast cancer].
Hasbini A; Le Péchoux C; Roche B; Pignol JP; Zelek L; Abdulkarim B; Arriagada R; Guinebretière JM; Tardivon A; Spielmann M; Habrand JL
Cancer Radiother; 2000; 4(4):265-73. PubMed ID: 10994390
[TBL] [Abstract][Full Text] [Related]
10. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
[TBL] [Abstract][Full Text] [Related]
11. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
Koh EH; Buzdar AU; Ames FC; Singletary SE; McNeese MD; Frye D; Holmes FA; Fraschini G; Hug V; Theriault RL
Cancer Chemother Pharmacol; 1990; 27(2):94-100. PubMed ID: 2249339
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study.
Rossi A; Molinari R; Boracchi P; Del Vecchio M; Marubini E; Nava M; Morandi L; Zucali R; Pilotti S; Grandi C
J Clin Oncol; 1988 Sep; 6(9):1401-10. PubMed ID: 3047335
[TBL] [Abstract][Full Text] [Related]
16. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
17. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
[TBL] [Abstract][Full Text] [Related]
20. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.
Ang PT; Buzdar AU; Smith TL; Kau S; Hortobagyi GN
J Clin Oncol; 1989 Nov; 7(11):1677-84. PubMed ID: 2809682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
